Pancreatic Cancer Therapy Market to 2025 – Global Analysis and Forecasts

Pancreatic Cancer Therapy Market to 2025 – Global Analysis and Forecasts

  • August 2018 •
  • 133 pages •
  • Report ID: 5500422 •
  • Format: PDF
The global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025.
The growth of the pancreatic cancer therapy market is primarily attributed to the increase in number of therapies launched in the market.The development of new drugs is thus expected to drive the growth of pancreatic cancer therapy market.

For instance, in October 2015, the FDA approved Onivyde drug by Merrimack Pharmaceuticals, Inc. as a part of treatment regimen for advanced pancreatic cancer. Some common side effects associated with chemotherapy drugs include diarrhea and abdominal cramping, fatigue, loss of appetite, change in food taste and others. Cancer cells that are rapidly growing are killed by chemotherapy drugs. However, these drugs travel throughout the body and thus can affect normal and healthy cells adversely. Blood-forming cells in the bone marrow, hair follicles and cell in the mouth, digestive tract, and reproductive system are likely to be affected by chemotherapeutic drugs. The current treatment options available for pancreatic cancer patients only help to extend the patients’ lives by a few months. This demands potential drugs that are able to enhance the effectiveness of chemotherapy drugs. Combination of two or more chemotherapy drugs are a suitable way out to increase the efficacy of the drug as well as proves advantageous in the treatment.
Global pancreatic cancer therapy market, based on the type was segmented into endocrine pancreatic cancer and exocrine pancreatic cancer.In 2017, the exocrine pancreatic cancer segment held the largest share of the pancreatic cancer therapy market, by type.

The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this cancer is majorly occurring cancer type among the two and thus is expected to have massive patient pool over the forecast years.
Global pancreatic cancer therapy market, based on the therapy was segmented into biologic, chemotherapy and others.In 2017, biologic therapy segment held the largest share of the pancreatic cancer therapy market, by therapy.

Moreover, the biologic therapy segment is expected to grow at the fastest rate during the coming years owing to increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies.
Some of the major primary and secondary sources for pancreatic cancer therapy included in the report are World Health Organization (WHO), American Society of Clinical Oncology, Pancreatic Cancer Action Network, National Institutes of Health, National Cancer Institute, Scientific American, American Cancer Society and Pancreatic Cancer Research.

Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the pancreatic cancer therapy market.
-Highlights key business priorities in order to assist companies to realign their business strategies.
-The key findings and recommendations highlight crucial progressive industry trends in the global pancreatic cancer therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
-Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
-Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
-Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.